Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Orphazyme Interim Condensed Consolidated Financial Statements First Half 2018 Presentation


Posted on: 22 Aug 18

Orphazyme A/S
Investor news                                                                                                                                     

No. 08/2018                                                                                                                                       
Company Registration No. 32266355


 

Copenhagen, August 22, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that the Company will be hosting an investor call at which Chief Executive Officer, Anders Hinsby, and Chief Financial Officer, Anders Vadsholt, will be presenting the Orphazyme Interim Condensed Consolidated Financial Statements First Half 2018. The presentation will be followed by a Q&A session.

The call will be held on: Tuesday, August 28, 2018 at 11.00 AM CET.

Dial-in details:

  • Denmark: +45 35 15 81 21
  • United Kingdom: +44 (0)330 336 9411
  • United States: +1 929-477-0324
     
  • Event Title: Orphazyme Interim Condensed Consolidated Financial Statements First Half 2018
  • Confirmation code: 2088051

The presentation will also be available via webcast: https://edge.media-server.com/m6/p/5hejv92c

After the call, a replay will be available by using the following dial-details (available until September 4, 2018):

  • Denmark: +45 70 14 50 87
  • United Kingdom: +44 (0)207 660 0134
  • United States: +1 719-457-0820
     
  • Confirmation code REPLAY: 2088051


About Orphazyme A/S
Orphazyme is a biopharmaceutical company focused on bringing novel treatments to patients living with life-threatening or debilitating rare diseases. Our research focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C, Gaucher disease, sporadic Inclusion Body Myositis, and Amyotrophic Lateral Sclerosis. The Denmark-based company is listed on Nasdaq Copenhagen (ORPHA.CO). For more information, please visit www.orphazyme.com.  

Attachment

GlobeNewswire
globenewswire.com

Last updated on: 23/08/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.